KNSA insider transactions
Kiniksa Pharmaceuticals International plc (KNSA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for KNSA
- Director Quart Barry D converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Popovits Kimberly J converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHAIRMAN & CEO Patel Sanj K converted options into 900,000 units of Class A Ordinary Share (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Mccain Tracey L converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Malley Thomas converted options into 2,799 units of Class A Ordinary Shares, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Levy Richard S converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 15% to 21,956 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Cole G Bradley converted options into 2,799 units of Class A Ordinary Share, increasing direct ownership by 22% to 15,345 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Baker Bros. Advisors Lp was granted 12,156 units of Class A Ordinary Shares (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF MEDICAL OFFICER Paolini John F. sold $3,137,823 worth of Class A Ordinary Share (58,424 units at $53.71) as part of a pre-agreed trading plan and exercised 58,424 units of Class A Ordinary Share at a strike of $10.36 (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHAIRMAN & CEO Patel Sanj K exercised 48,565 units of Class A Ordinary Share at a strike of $30.93 and sold $2,623,481 worth of Class A Ordinary Share (48,565 units at $54.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHAIRMAN & CEO Patel Sanj K exercised 508,339 units of Class A Ordinary Share at a strike of $13.45 and sold $26,415,228 worth of Class A Ordinary Share (508,339 units at $51.96) as part of a pre-agreed trading plan (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Quart Barry D exercised 13,099 units of Class A Ordinary Share at a strike of $14.33 and sold $656,260 worth of Class A Ordinary Share (13,099 units at $50.10) as part of a pre-agreed trading plan (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Megna Michael R4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Moat Ross4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Tessari Eben4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Ragosa Mark4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Patel Sanj K4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Paolini John F.4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Moat Ross4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Megna Michael R4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Quart Barry D4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Tessari Eben4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Ragosa Mark4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Patel Sanj K4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Paolini John F.4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Moat Ross4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Megna Michael R4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Kiniksa Pharmaceuticals International plc4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF MEDICAL OFFICER Paolini John F. exercised 40,000 units of Class A Ordinary Share at a strike of $10.36 and sold $1,792,940 worth of Class A Ordinary Share (40,000 units at $44.82) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Quart Barry D exercised 2,800 units of Class A Ordinary Share at a strike of $15.47 and sold $126,000 worth of Class A Ordinary Share (2,800 units at $45.00) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF FINANCIAL OFFICER Ragosa Mark exercised 10,845 units of Class A Ordinary Share at a strike of $13.87 and sold $772,254 worth of Class A Ordinary Share (17,845 units at $43.28), decreasing direct ownership by 37% to 12,086 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Quart Barry D exercised 15,960 units of Class A Ordinary Share at a strike of $15.47 and sold $721,635 worth of Class A Ordinary Share (15,960 units at $45.22) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Levy Richard S converted options into 683 units of Class A Ordinary Share, increasing direct ownership by 4% to 19,157 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF FINANCIAL OFFICER Ragosa Mark sold $502,680 worth of Class A Ordinary Share (12,000 units at $41.89), decreasing direct ownership by 39% to 19,086 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Quart Barry D exercised 20,129 units of Class A Ordinary Share at a strike of $10.36 and sold $835,555 worth of Class A Ordinary Share (20,129 units at $41.51) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF OPERATING OFFICER Tessari Eben exercised 6,000 units of Class A Ordinary Share at a strike of $8.83 and sold $500,715 worth of Class A Ordinary Share (12,048 units at $41.56), decreasing direct ownership by 27% to 16,666 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF FINANCIAL OFFICER Ragosa Mark exercised 42,841 units of Class A Ordinary Share at a strike of $11.34 and sold $1,777,473 worth of Class A Ordinary Share (42,841 units at $41.49) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- SEC Form 4 filed by Kiniksa Pharmaceuticals International plc4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $514,224 worth of Class A Ordinary Share (12,470 units at $41.24), decreasing direct ownership by 21% to 22,714 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHAIRMAN & CEO Patel Sanj K gifted 171,794 units of Class A Ordinary Share and received a gift of 171,794 units of Class A Ordinary Share, closing all direct ownership in the company (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF FINANCIAL OFFICER Ragosa Mark exercised 19,900 units of Class A Ordinary Share at a strike of $30.93 and sold $814,706 worth of Class A Ordinary Share (19,900 units at $40.94) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF MEDICAL OFFICER Paolini John F. exercised 82,542 units of Class A Ordinary Share at a strike of $6.60 and sold $3,065,610 worth of Class A Ordinary Share (82,542 units at $37.14) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF FINANCIAL OFFICER Ragosa Mark exercised 100 units of Class A Ordinary Share at a strike of $30.93 and sold $4,100 worth of Class A Ordinary Share (100 units at $41.00) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHAIRMAN & CEO Patel Sanj K exercised 257,969 units of Class A Ordinary Share at a strike of $3.80 and sold $10,023,532 worth of Class A Ordinary Share (257,969 units at $38.86) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF ACCOUNTING OFFICER Megna Michael R exercised 39,435 units of Class A Ordinary Share at a strike of $11.59 and sold $1,962,781 worth of Class A Ordinary Share (50,490 units at $38.87), decreasing direct ownership by 29% to 27,046 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $465,843 worth of Class A Ordinary Share (12,368 units at $37.67), decreasing direct ownership by 17% to 28,684 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF ACCOUNTING OFFICER Megna Michael R converted options into 175 units of Class A Ordinary Share and covered exercise/tax liability with 85 units of Class A Ordinary Share, increasing direct ownership by 0.24% to 38,101 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF OPERATING OFFICER Tessari Eben exercised 42,000 units of Class A Ordinary Share at a strike of $17.92 and sold $1,609,860 worth of Class A Ordinary Share (42,000 units at $38.33) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $597,976 worth of Class A Ordinary Share (16,400 units at $36.46), decreasing direct ownership by 22% to 34,552 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF OPERATING OFFICER Tessari Eben exercised 98,660 units of Class A Ordinary Share at a strike of $15.51 and sold $3,506,278 worth of Class A Ordinary Share (98,660 units at $35.54) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF CORP. & COMM. OFFICER Moat Ross sold $124,397 worth of Class A Ordinary Share (3,523 units at $35.31), decreasing direct ownership by 27% to 9,415 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF OPERATING OFFICER Tessari Eben exercised 23,300 units of Class A Ordinary Share at a strike of $10.04, covered exercise/tax liability with 3,972 units of Class A Ordinary Share and sold $535,730 worth of Class A Ordinary Share (15,091 units at $35.50), increasing direct ownership by 11% to 44,452 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF ACCOUNTING OFFICER Megna Michael R exercised 20,627 units of Class A Ordinary Share at a strike of $9.56, covered exercise/tax liability with 4,657 units of Class A Ordinary Share and sold $383,240 worth of Class A Ordinary Share (11,000 units at $34.84), increasing direct ownership by 15% to 38,011 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF CORP. & COMM. OFFICER Moat Ross converted options into 6,823 units of Class A Ordinary Share and covered exercise/tax liability with 3,300 units of Class A Ordinary Share, increasing direct ownership by 37% to 12,938 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF MEDICAL OFFICER Paolini John F. converted options into 7,597 units of Class A Ordinary Share and covered exercise/tax liability with 3,676 units of Class A Ordinary Share, increasing direct ownership by 7% to 61,324 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF FINANCIAL OFFICER Ragosa Mark covered exercise/tax liability with 3,820 units of Class A Ordinary Share and converted options into 7,897 units of Class A Ordinary Share, increasing direct ownership by 15% to 31,086 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHAIRMAN & CEO Patel Sanj K converted options into 29,280 units of Class A Ordinary Share and covered exercise/tax liability with 14,160 units of Class A Ordinary Share, increasing direct ownership by 16% to 111,794 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF OPERATING OFFICER Tessari Eben exercised 6,500 units of Class A Ordinary Share at a strike of $8.83 and sold $547,141 worth of Class A Ordinary Share (16,200 units at $33.77), decreasing direct ownership by 19% to 40,215 units (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- Director Malley Thomas exercised 177,769 units of Class A Ordinary Shares at a strike of $10.21 and sold $5,859,815 worth of Class A Ordinary Shares (177,769 units at $32.96) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)
- CHIEF MEDICAL OFFICER Paolini John F. exercised 29,325 units of Class A Ordinary Share at a strike of $3.80 and sold $954,529 worth of Class A Ordinary Share (29,325 units at $32.55) (SEC Form 4)4 - Kiniksa Pharmaceuticals International, plc (0001730430) (Issuer)